Pfizer receives FDA approval for the use of Vfend to treat esophageal candidiasis.
The company notes that in immunocompromised patients, esophageal candidiasis may coat much of the surface of the mouth resulting in pain and difficulty swallowing and may ultimately progress to more serious, invasive disease.
Pfizer says the basis for the FDA approval was a clinical trial with immunocompromised patients conducted at study sites in 15 countries. Patients received either Vfend or fluconazole. Those treated with Vfend had success rates of 98%, compared to 95% for fluconazole, the company reports.
Vfend was initially approved in the US for the primary treatment of acute invasive aspergillosis and salvage therapy for rare but serious infections caused by the pathogens Scedosporium apiospermum and Flusarium spp. The company is continuing to study the use of Vfend for the treatment of serious fungal infections.
Contact: www.pfizer.com or www.vfend.com.
|Printer friendly Cite/link Email Feedback|
|Article Type:||Brief Article|
|Date:||Nov 30, 2003|
|Previous Article:||First liver transplants in Vietnam expected to be performed next year.|
|Next Article:||Medtronic receives Humanitarian Device Exemption from FDA for heart repair product for children.|